Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 7, 2004
Last updated: January 23, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):